AXL and hepatocellular carcinoma: Interestingly, cells lacking Axl after CRISPR/Cas9-mediated genomic editing were more sensitive to TKIs supporting the hypothesis that Axl favors tolerance against targeted therapies in HCC (Figure 1C).